Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only
详细信息 查看全文
- 作者：M. M. Chao ; J. S. Kuehl ; G. Strauss ; H. Hanenberg ; D. Schindler…
- 关键词：Fanconi anemia ; Non ; radiation conditioning ; Fludarabine ; based conditioning ; Alternative donor HSCT
- 刊名：Annals of Hematology
- 出版年：2015
- 出版时间：August 2015
- 年：2015
- 卷：94
- 期：8
- 页码：1311-1318
- 全文大小：311 KB
- 参考文献：1.Berger R, Bernheim A, Gluckman E et al (1980) In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. Br J Haematol 45(4):565-68PubMed View Article
2.Auerbach AD, Adler B, O'Reilly RJ et al (1983) Effect of procarbazine and cyclophosphamide on chromosome breakage in Fanconi anemia cells: relevance to bone marrow transplantation. Cancer Genet Cytogenet 9(1):25-6PubMed View Article
3.Gluckman E, Devergie A, Dutreix J (1983) Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol 54(3):431-40PubMed View Article
4.Guardiola P, Socie G, Li X et al (2004) Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood 103(1):73-7. doi:10.-182/?blood-2003-06-2146 PubMed View Article
5.Gluckman E, Berger R, Dutreix J (1984) Bone marrow transplantation for Fanconi anemia. Semin Hematol 21(1):20-6PubMed
6.Kapelushnik J, Or R, Slavin S et al (1997) A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia. Bone Marrow Transplant 20(12):1109-110. doi:10.-038/?sj.?bmt.-701016 PubMed View Article
7.Bitan M, Or R, Shapira MY et al (2006) Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. Biol Blood Marrow Transplant 12(7):712-18. doi:10.-016/?j.?bbmt.-006.-3.-02 PubMed View Article
8.Tan PL, Wagner JE, Auerbach AD et al (2006) Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatr Blood Cancer 46(5):630-36. doi:10.-002/?pbc.-0538 PubMed View Article
9.Wagner JE, Eapen M, MacMillan ML et al (2007) Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 109(5):2256-262. doi:10.-182/?blood-2006-07-036657 PubMed Central PubMed View Article
10.Drobyski WR (2000) Evolving strategies to address adverse transplant outcomes associated with T cell depletion. J Hematother Stem Cell Res 9(3):327-37PubMed View Article
11.Guardiola P, Pasquini R, Dokal I et al (2000) Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood 95(2):422-29PubMed
12.Ayas M, Al-Seraihi A, El-Solh H et al (2012) The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells. Biol Blood Marrow Transplant 18(4):627-32. doi:10.-016/?j.?bbmt.-011.-8.-15 PubMed View Article
13.Ayas M, Al-Jefri A, Al-Seraihi A et al (2008) Matched-related allogeneic stem cell transplantation in Saudi patients with Fanconi anemia: 10?year's experience. Bone Marrow Transplant 42(Suppl 1):S45–S48. doi:10.-038/?bmt.-008.-14 PubMed View Article
14.MacMillan ML, Wagner JE (2010) Haematopoeitic cell transplantation for Fanconi anaemia: when and how? Br J Haematol 149(1):14-1. doi:10.-111/?j.-365-2141.-010.-8078.?x PubMed View Article
15.Pasquini R, Carreras J, Pasquini MC et al (2008) HLA-matched sibling hematopoietic stem cell transplantation for Fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant 14(10):1141-147. doi:10.-016/?j.?bbmt.-008.-6.-20 PubMed Central PubMed View Article
16.MacMillan ML, Blazar BR, Defor TE et al (2012) Alternative donor hematopoietic cell transplantation for patients with Fanconi anemia. ASH Ann Meet Abstr 120(21):3081
17.Bisset LR, Lung TL, Kaelin M et al (2004) Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 72(3):203-12. doi:10.-046/?j.-902-4441.-003.-0199.?x PubMed View Article
18.Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825-28PubMed
19.Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945-56. doi:10.-016/?j.?bbmt.-005.-9.-04 PubMed View Article
20.Dignan FL, Amrolia P, Clark A et al (2012) Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 158(1):46-1. doi:10.-111/?j.-365-2141.-012.-9128.?x PubMed View Article
21.Dignan FL, Clark A, Amrolia P et al (2012) Diagnosis and management of acute graft-versus- - 作者单位：M. M. Chao (1)
J. S. Kuehl (2)
G. Strauss (2)
H. Hanenberg (3) (4)
D. Schindler (5)
H. Neitzel (6)
C. Niemeyer (7)
I. Baumann (8)
H. von Bernuth (10) (9)
J. Rascon (11) (12)
M. Nagy (11)
M. Zimmermann (1)
C. P. Kratz (1)
W. Ebell (2)
1. Department of Pediatric Hematology Oncology, Hannover Medical School, Carl-Neuberg Strasse 1, 30625, Hannover, Germany
2. Department of Pediatric Oncology, Hematology, and Stem Cell Transplantation, Charité University Medicine Berlin, Berlin, Germany
3. Department of Pediatrics and Human and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
4. Department of Otorhinolaryngology, Head and Neck Surgery, Heinrich Heine University, Düsseldorf, Germany
5. Department of Human Genetics, University of Wuerzberg, Wuerzberg, Germany
6. Institute of Medical and Human Genetics, Charité University Medicine Berlin, Berlin, Germany
7. Department of Pediatric Hematology Oncology, Freiburg University School of Medicine, Freiburg, Germany
8. Department of Pathology, Boeblingen Hospital, Clinical Centre South West, Boeblingen, Germany
10. Department of Immunology, Laboratory Berlin Charité Vivantes GmbH, Berlin, Germany
9. Department of Pediatric Pulmonology and Immunology, Charité University Medicine Berlin, Berlin, Germany
11. Institute of Legal and Forensic Medicine, Charité University Medicine Berlin, Berlin, Germany
12. Center for Pediatric Oncology and Hematology, Vilnius University, Vilnius, Lithuania - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Hematology
Oncology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-0584
文摘
Fanconi anemia (FA) is a genomic instability syndrome associated with bone marrow failure, myelodysplastic syndrome (MDS), and/or acute myeloid leukemia (AML) requiring hematopoietic stem cell transplantation (HSCT) to restore normal hematopoiesis. Although low-intensity fludarabine-based preparative regimens without radiation confer excellent outcomes in FA HSCTs with HLA-matched sibling donors, outcomes for FA patients with alternative donors are less encouraging, albeit improving. We present our experience with 17 FA patients who completed mismatched related or unrelated donor HSCT using a non-radiation fludarabine-based preparative regimen at Charité University Medicine Berlin. All patients engrafted; however, one patient had unstable chimerism in the setting of multi-viral infections that necessitated a stem cell boost to revert to full donor chimerism. Forty-seven percent of patients developed grade I acute graft-verus-host disease (aGVHD). No grade II–IV aGVHD or chronic graft-versus-host disease of any severity occurred. At a median follow-up of 30?months, 88?% of patients are alive with normal hematopoiesis. Two patients died of infections 4?months post-transplantation. These results demonstrate that short-term outcomes for FA patients with mismatched and unrelated donor HSCTs can be excellent using chemotherapy only conditioning. Viral reactivation, however, was a major treatment-related complication.